JP7699551B2 - コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用 - Google Patents

コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用 Download PDF

Info

Publication number
JP7699551B2
JP7699551B2 JP2021575316A JP2021575316A JP7699551B2 JP 7699551 B2 JP7699551 B2 JP 7699551B2 JP 2021575316 A JP2021575316 A JP 2021575316A JP 2021575316 A JP2021575316 A JP 2021575316A JP 7699551 B2 JP7699551 B2 JP 7699551B2
Authority
JP
Japan
Prior art keywords
compound
mitochondrial
isolated compound
complex
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538009A (ja
JPWO2020254484A5 (enExample
Inventor
ジョアキム ハンスン マグナス
グローンベルグ アルバー
エスキル エルメール マッツ
リチャード ファーメリー マーク
ジェームズ モス スティーブン
ロバート ウェブスター リー
アラン グレゴリー マシュー
Original Assignee
アブリバ エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリバ エービー filed Critical アブリバ エービー
Publication of JP2022538009A publication Critical patent/JP2022538009A/ja
Publication of JPWO2020254484A5 publication Critical patent/JPWO2020254484A5/ja
Priority to JP2024176276A priority Critical patent/JP2025004155A/ja
Application granted granted Critical
Publication of JP7699551B2 publication Critical patent/JP7699551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2021575316A 2019-06-19 2020-06-18 コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用 Active JP7699551B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176276A JP2025004155A (ja) 2019-06-19 2024-10-08 コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970384 2019-06-19
DKPA201970384 2019-06-19
DKPA201970382 2019-06-19
DKPA201970383 2019-06-19
PCT/EP2020/066923 WO2020254484A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176276A Division JP2025004155A (ja) 2019-06-19 2024-10-08 コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用

Publications (3)

Publication Number Publication Date
JP2022538009A JP2022538009A (ja) 2022-08-31
JPWO2020254484A5 JPWO2020254484A5 (enExample) 2023-06-28
JP7699551B2 true JP7699551B2 (ja) 2025-06-27

Family

ID=71130953

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575316A Active JP7699551B2 (ja) 2019-06-19 2020-06-18 コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
JP2024176276A Pending JP2025004155A (ja) 2019-06-19 2024-10-08 コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176276A Pending JP2025004155A (ja) 2019-06-19 2024-10-08 コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用

Country Status (11)

Country Link
US (2) US11565998B2 (enExample)
EP (2) EP4360708A3 (enExample)
JP (2) JP7699551B2 (enExample)
KR (1) KR102871719B1 (enExample)
CN (1) CN113993842B (enExample)
AU (1) AU2020298031B2 (enExample)
CA (1) CA3143112A1 (enExample)
IL (1) IL288990B2 (enExample)
MA (1) MA56506A (enExample)
MX (1) MX2021015137A (enExample)
WO (1) WO2020254484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155231A1 (en) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Novel cell-permeable succinate compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
CN106255509A (zh) * 2014-04-08 2016-12-21 纽维制药有限公司 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155231A1 (en) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Novel cell-permeable succinate compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Murli, S et al，Chemobiosynthesis of Novel 6-Deoxyerythronolide B Analogues by Mutation of the Loading Module of 6-Deoxyerythronolide B Synthase 1，Applied and Environmental Microbiology，2005年08月，vol 71, No. 8，p.p.4503-4509
第十六改正 日本薬局方，2011年，pp.64-68,2070

Also Published As

Publication number Publication date
US11565998B2 (en) 2023-01-31
US20220162162A1 (en) 2022-05-26
MX2021015137A (es) 2022-01-18
IL288990B2 (en) 2025-09-01
JP2025004155A (ja) 2025-01-14
EP4360708A2 (en) 2024-05-01
EP4360708A3 (en) 2024-12-25
KR102871719B1 (ko) 2025-10-15
JP2022538009A (ja) 2022-08-31
CN113993842A (zh) 2022-01-28
EP3986862B1 (en) 2024-01-24
KR20220024780A (ko) 2022-03-03
US20230033294A1 (en) 2023-02-02
US12162824B2 (en) 2024-12-10
EP3986862A1 (en) 2022-04-27
AU2020298031B2 (en) 2025-12-18
EP3986862C0 (en) 2024-01-24
CA3143112A1 (en) 2020-12-24
IL288990A (en) 2022-02-01
CN113993842B (zh) 2024-07-16
WO2020254484A1 (en) 2020-12-24
BR112021024510A2 (pt) 2022-01-18
AU2020298031A1 (en) 2022-02-03
IL288990B1 (en) 2025-05-01
MA56506A (fr) 2022-04-27

Similar Documents

Publication Publication Date Title
US9439915B2 (en) Activated nitric oxide donors and methods of making and using thereof
JP2021502323A (ja) 重水素濃縮ｎ−アセチルシステインアミド（ｄ−ｎａｃａ，ｄｅｕｔｅｒｉｕｍ−ｅｎｒｉｃｈｅｄ ｎ−ａｃｅｔｙｌｃｙｓｔｅｉｎｅ ａｍｉｄｅ）及び（２ｒ，２ｒ’）−３，３’−ジスルファンジイルビス（２−アセトアミドプロパンアミド）（ｄｉｎａｃａ）を作製する、並びに酸化ストレスが関与する疾患を治療するためにｄ−ｎａｃａ及びｄｉｎａｃａを使用する方法
JP2020532535A (ja) セピアプテリンを含む医薬組成物及びその使用
EP4385987A1 (en) Impurity in plinabulin or preparation thereof, and use thereof
JP2025004155A (ja) コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
KR20220131186A (ko) L-세린 또는 이의 약제학적으로 허용가능한 염의 액상 제제 및 이의 제조방법
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
KR102667351B1 (ko) 사쿠비트릴 및 아질사르탄 공형성화물, 및 이를 포함하는 약제학적 조성물
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
EA045539B1 (ru) Сукцинатное пролекарство, композиции, содержащие сукцинатное пролекарство, и их применение
US9751840B2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
BR112021024510B1 (pt) 3-[(2-acetilaminoetiltio)carbonil]propionato de metila isolado, cosmecêutico, nutricosméticos, bebida energética, e, composição farmacêutica
WO2012027455A1 (en) Glutathione-lanthionine compounds and methods related thereto
WO2017060418A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
HK40085297A (en) Impurity in plinabulin or preparation thereof, and use thereof
WO2017075145A1 (en) Quinoline amides and methods of using same
US10058618B2 (en) PAK1-blocking 1,2,3-triazolyl esters
EP2638902B1 (en) Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
WO2017060422A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250617

R150 Certificate of patent or registration of utility model

Ref document number: 7699551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150